← Back to Search

Procedure

Speech Therapy + tDCS for Aphasia

N/A
Waitlist Available
Led By Maya Henry, PhD
Research Sponsored by University of Texas at Austin
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Score of 20 or higher on the Mini-Mental State Examination
Meets diagnostic criteria for PPA
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change from pre-treatment to one month and three months after onset of treatment in each phase (stimulation and sham)
Awards & highlights

Study Summary

This trial aims to improve quality of life for people with PPA by combining speech-language telerehabilitation and tailored neuromodulatory treatment in their homes.

Who is the study for?
This trial is for adults with Primary Progressive Aphasia who can think clearly enough (score of 20+ on a mental state exam), see and hear well (with aids if needed), undergo an MRI, have internet access, and a partner to help them through the study. It's not for those with other neurological issues, history of stroke/epilepsy/severe brain injury, or contraindications for tDCS/MRI.Check my eligibility
What is being tested?
The trial tests whether home-based brain stimulation paired with speech-language therapy via video call helps people with different types of PPA. Participants will receive either real or sham brain stimulation while engaging in language exercises designed to improve communication.See study design
What are the potential side effects?
Transcranial Direct Current Stimulation may cause mild side effects like itching, tingling at the electrode site, headache, fatigue or nausea. However, it's generally considered safe and these sensations typically fade after the session.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My mental state score is 20 or higher.
Select...
I have been diagnosed with primary progressive aphasia.
Select...
I have been diagnosed with a specific type of primary progressive aphasia.
Select...
I am willing and able to have an MRI scan of my brain.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change from pre-treatment to one month and three months after onset of treatment in each phase (stimulation and sham)
This trial's timeline: 3 weeks for screening, Varies for treatment, and change from pre-treatment to one month and three months after onset of treatment in each phase (stimulation and sham) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
RS-LRT arm: Change in spoken naming
RS-VISTA arm: Change in script production accuracy
Secondary outcome measures
Care Partner Survey
Change on Aphasia Impact Questionnaire
Change on Communication Confidence Rating Scale for Aphasia
+2 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: RS-VISTAExperimental Treatment3 Interventions
Group II: RS-LRTExperimental Treatment3 Interventions

Find a Location

Who is running the clinical trial?

University of California, San FranciscoOTHER
2,518 Previous Clinical Trials
15,241,719 Total Patients Enrolled
University of Texas at AustinLead Sponsor
356 Previous Clinical Trials
81,469 Total Patients Enrolled
Maya Henry, PhDPrincipal InvestigatorUniversity of Texas at Austin

Media Library

Lexical Retrieval Training (LRT) (Procedure) Clinical Trial Eligibility Overview. Trial Name: NCT05901233 — N/A
Primary Progressive Aphasia Research Study Groups: RS-VISTA, RS-LRT
Lexical Retrieval Training (LRT) (Procedure) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05901233 — N/A
Primary Progressive Aphasia Clinical Trial 2023: Lexical Retrieval Training (LRT) Highlights & Side Effects. Trial Name: NCT05901233 — N/A
~0 spots leftby Jun 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top